4-[[(4-Fluorophenyl)imino]methyl]-phenol CAS 3382-63-6 Ezetimibe Entèmedyè Pite ≥99.0% Faktori
Manifakti Pwovizyon pou;Segondè Kalite ak pri konpetitif
Ekipman komèsyal Ezetimibe (CAS: 163222-33-1) Entèmedyè ki gen rapò:
(S)-(+)-4-Phenyl-2-oxazolidinone CAS: 99395-88-7
(R)-(+)-2-Methyl-CBS-oxazaborolidine CAS: 112022-83-0
4-(4-Fluorobenzoyl)butyric asid CAS: 149437-76-3
4-[[(4-Fluorophenyl)imino]methyl]-phenol CAS: 3382-63-6
N-(4-(Benzyloxy)benzyliden)-4-fluoroaniline CAS: 70627-52-0
(3R,4S)-4-[4-(Benzyloxy)phenyl]-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]azetidin-2-one CAS: 190595-65 -4
(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone CAS: 189028-93-1
(4S)-3-[(5S)-5-(4-Fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one CAS: 189028-95-3
Ezetimibe CAS: 163222-33-1
Non Chimik | 4-[[(4-Fluorophenyl)imino]methyl]-phenol |
Nimewo CAS | 3382-63-6 |
Nimewo CAT | RF-PI145 |
Estati Stock | Nan Stock, Pwodiksyon Echèl Jiska Tòn |
Fòmil molekilè | C13H10FNO |
Pwa molekilè | 215.22 |
Pwen k ap fonn | 179.0 a 183.0 ℃ |
Mak | Ruifu Chimik |
Atik | Espesifikasyon |
Aparans | Off-Blan poud blan |
Pite / Metòd analiz | ≥99.0% (HPLC) |
Pèt sou siye | ≤0.50% |
Single enpurte | ≤0.50% |
Enpurte total | ≤1.0% |
Metal lou | ≤20ppm |
Tès Creole | Enterprise Standard |
Itilizasyon | Ezetimibe (CAS: 163222-33-1) Entèmedyè |
Pake: Boutèy, sak papye aliminyòm, tanbou katon, 25kg / tanbou, oswa selon kondisyon kliyan an.
Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè, imidite ak ensèk nuizib.
![1](https://www.ruifuchemical.com/uploads/15.jpg)
![2](https://www.ruifuchemical.com/uploads/23.jpg)
Shanghai Ruifu Chemical Co, Ltd se manifakti dirijan ak founisè nan 4-[[(4-Fluorophenyl)imino]methyl]-phenol (CAS: 3382-63-6) ak bon jan kalite segondè, li se yon entèmedyè nan Ezetimibe ( CAS: 163222-33-1).Ezetimibe se yon dwòg anti-iperlipidemi ki itilize pou bese nivo kolestewòl nan plasma.Ezetimibe se yon inibitè transpò kolestewòl ki mare ak NPC1L1.Li endike kòm yon terapi adjwen nan rejim alimantè pou rediksyon wo nivo total-C, LDL-C, ak ApoB nan pasyan ki soufri prensipal (eterozigot familyal ak ki pa fanmi) hypercholesterolemia.